Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Healthcare company Novo Nordisk ($NVO) has reported promising results from its latest clinical trial for its obesity treatment. Notably, tripling ...

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient ...

At least two retrospective observational studies now suggest that tirzepatide safely reduces weight, A1c, and insulin ...

When Sarah Vogel discovered the price of her monthly weight-loss jab was soaring, she was devastated. “My heart sank,” she ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis ...

Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this ...

The restructuring marks the first major action authorised by new CEO Mike Doustdar in a bid to turn the company’s fortunes ...